CAPR
Not the kind of panel review you want
Capricor’s Thursday turned into a full-on trapdoor moment. An FDA advisory committee voted 9-3 that the company hasn’t shown enough evidence that Deramiocel actually works for Duchenne muscular dystrophy, which is basically the regulatory equivalent of the judge leaning back and saying, “Convince me.”
The stock didn’t exactly take the subtle hint — shares sank 52.36% to $3.13 and tagged a fresh 52-week low. When a biotech gets hit this hard, it’s usually because the market is suddenly reassessing the odds of a clean approval runway, not just taking a little profit off the table.
Why this matters
The FDA staff briefing was already waving yellow flags, saying the company’s late-stage data didn’t provide substantial evidence of effectiveness. The panel basically echoed that concern, citing small and variable changes in upper limb function and cardiac measures that were hard to interpret.
For investors, the big issue is this: Capricor now has a much tougher story to sell ahead of the FDA’s August 22nd PDUFA date. Even with the company pointing to a Lancet-published HOPE-3 paper and calling the trial a landmark, the market is clearly deciding that peer-reviewed bragging rights don’t automatically equal regulatory confidence.
The biotech version of a plot twist
Biotech names can swing from “science breakthrough” to “please read the footnotes” in about 12 trading hours, and CAPR just lived that entire arc. The company still has a case to make, but after this panel vote, the burden just got heavier.
Big picture: the market is treating this like a serious approval-risk event, not a routine volatility blip. In biotech, the FDA doesn’t just move the goalposts — sometimes it moves the whole stadium.